<DOC>
	<DOCNO>NCT00110513</DOCNO>
	<brief_summary>Patients hereditary antithrombin deficiency increase risk venous thrombosis pulmonary embolism , particularly certain high risk procedure . The trial focus patient confirm hereditary antithrombin deficiency undergo surgical procedure induced/spontaneous labor delivery , and/or caesarean section . The study assess incidence thromboembolic event follow prophylactic intravenous administration recombinant human antithrombin ( rhAT ) patient hereditary antithrombin ( AT ) deficiency situation usually associate high risk thromboembolic event .</brief_summary>
	<brief_title>Recombinant Human Antithrombin ( rhAT ) Patients With Hereditary Antithrombin Deficiency Undergoing Surgery Delivery</brief_title>
	<detailed_description>GTC Biotherapeutics establish clinical trial site Europe , Canada , Australia , Austria Canada . GTC Biotherapeutics provide international clinical team support site registration requirement patient identified treatment . GTC Biotherapeutics also provide consultation help evaluate patient eligibility . In September 2006 , GTC Biotherapeutics modify exclusion criterion 1 ( ) allow participation previously exclude patient hereditary thrombophilic disorder Factor V Leiden prothrombin gene mutation ( G20210A ) .</detailed_description>
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>1 . Have hereditary antithrombin deficiency ( HD ) personal history venous thromboembolic event . 2 . Have history HD include 2 plasma AT activity value â‰¤ 60 % . 3 . Be schedule elective procedure ( ) know associate high risk occurrence DVT . This include nonpregnant surgical patient pregnant patient schedule caesarean section delivery induction . 4 . Be least 18 year age , exceed 80 year age . 5 . Have sign inform consent form . 6 . Have negative serum pregnancy test screen negative urine pregnancy test baseline . This apply female nonpregnant surgical patient childbearing potential . 7 . Are able comply requirement study protocol . In addition , hospitalize pregnant HD patient active labor eligible HD patient previously treat rhAT allow entry study . 1 . Patients diagnosis another hereditary thrombophilic disorder ( e.g . activate protein C ( APC ) resistance/Factor V Leiden , Protein S C deficiency , prothrombin gene mutation ( G20210A ) , acquire ( lupus anticoagulant ) thrombophilic disorder ) . 2 . Patients baseline bilateral ultrasound positive acute DVT baseline diagnostic testing ( require ) positive thromboembolic event acute DVT . 3 . Patients know allergy goat goat product . 4 . Patients participate study employ different investigational drug within 30 day start participation current trial . 5 . Patients use fondaparinux sodium oral thrombin inhibitor , ximelagatran , expect treat fondaparinux sodium ximelagatran study period ( 7 day stop treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Antithrombin Deficiency , Congenital Hereditary</keyword>
	<keyword>Antithrombin III Deficiency</keyword>
	<keyword>ATIII</keyword>
	<keyword>Hereditary Antithrombin Deficiency ( HD )</keyword>
</DOC>